Brainstorm Cell Therapeutics Shares Halted, FDA Advisory Committee Meeting To Review NurOwn For ALS Scheduled To Take Place 10:00 a.m. To 6:00 p.m. ET
Portfolio Pulse from Benzinga Newsdesk
Shares of Brainstorm Cell Therapeutics have been halted in anticipation of an FDA Advisory Committee meeting. The meeting, scheduled to take place from 10:00 a.m. to 6:00 p.m. ET, will review NurOwn, Brainstorm's treatment for ALS.
September 27, 2023 | 12:20 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Brainstorm Cell Therapeutics' shares have been halted ahead of an FDA Advisory Committee meeting to review NurOwn, their ALS treatment. The outcome of this meeting could significantly impact the company's stock.
The halt in trading of Brainstorm Cell Therapeutics' shares indicates that the market is awaiting the outcome of the FDA meeting. The review of NurOwn, if positive, could lead to increased investor confidence and a potential rise in the company's stock. Conversely, a negative outcome could lead to a drop in stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100